Significance of neurochemical parameters in the preclinical evaluation of neuroleptic drugs.
D000818:Animals; D014150:Antipsychotic Agents / Q000633:toxicity*; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D001923:Brain Chemistry / Q000187:drug effects*; D003024:Clozapine / Q000494:pharmacology; D003342:Corpus Striatum / Q000033:anatomy & histology / Q000187:drug effects; D004298:Dopamine / Q000502:physiology; D004353:Drug Evaluation, Preclinical; D006220:Haloperidol / Q000494:pharmacology; D009434:Neural Pathways / Q000033:anatomy & histology / Q000187:drug effects; D009474:Neurons / Q000187:drug effects; D010275:Parasympathetic Nervous System / Q000187:drug effects; D011180:Postmortem Changes; D013378:Substantia Nigra / Q000033:anatomy & histology / Q000187:drug effects; D014439:Tyramine / Q000031:analogs & derivatives / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D014150:Antipsychotic Agents; D005680:gamma-Aminobutyric Acid; D003024:Clozapine; D006220:Haloperidol; D004298:Dopamine; D014439:Tyramine